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Abstract
Background: Multimorbidity is common in stroke, but the risk factors and effects on mortality remain poorly 
understood. Objective: To examine multimorbidity and its associations with sociodemographic/lifestyle risk 
factors and all-cause mortality in UK Biobank participants with stroke or transient ischaemic attack (TIA). 
Design: Data were obtained from an anonymized community cohort aged 40–72 years. Overall, 42 comor-
bidities were self-reported by those with stroke or TIA. Relative risk ratios demonstrated associations between 
participant characteristics and number of comorbidities. Hazard ratios demonstrated associations between the 
number and type of comorbidities and all-cause mortality. Results were adjusted for age, sex, socioeconomic 
status, smoking, and alcohol intake. Data were linked to national mortality data. Median follow-up was 7 years. 
Results: Of 8,751 participants (mean age 60.9±6.7 years) with stroke or TIA, the all-cause mortality rate over 
7 years was 8.4%. Over 85% reported ≥1 comorbidities. Age, socioeconomic deprivation, smoking and less 
frequent alcohol intake were associated with higher levels of multimorbidity. Increasing multimorbidity was 
associated with higher all-cause mortality. Mortality risk was double for those with ≥5 comorbidities compared 
to those with none. Having cancer, coronary heart disease, diabetes, or chronic obstructive pulmonary dis-
ease significantly increased mortality risk. Presence of any cardiometabolic comorbidity significantly increased 
mortality risk, as did any non-cardiometabolic comorbidity. Conclusions: In stroke survivors, the number of 
comorbidities may be a more helpful predictor of mortality than type of condition. Stroke guidelines should take 
greater account of comorbidities, and interventions are needed that improve outcomes for people with multi-
morbidity and stroke. 
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rising and that this creates challenges for those providing 
healthcare [1]. People with higher levels of multimor-
bidity are more likely to be prescribed higher numbers 
of medications [2,3], placing them at greater risk of dis-
ease–disease and disease–drug interactions [4,5]. It has 
been shown that multimorbidity is more common and 
occurs earlier in those who are more socioeconomically 
deprived [1]. Management of patients with multimor-
bidity can be challenging for clinicians due to a lack of 
evidence about how these factors relate to health-related 
outcomes. 
Introduction
It is well known that the prevalence of multimorbidity 
(the presence of two or more long-term conditions) is 
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Multimorbidity is common in stroke. Approximately 
94% of those who have suffered a stroke have at least one 
other long-term condition and 10% suffer from seven 
or more [2]. Current stroke guidelines and healthcare 
services are not designed optimally for those with mul-
timorbidity. As a result, those with stroke describe their 
healthcare as fragmented and poorly coordinated [6]. 
Information about which individuals with stroke are at 
risk of multimorbidity and examination of the relation-
ship with health-related outcomes is essential to inform 
the design of stroke services.
There currently is a poor understanding of the risk fac-
tors and consequences of multimorbidity in stroke. Older 
age has been shown to be associated with higher numbers of 
morbidities [7], but little is known about the relationships, 
if any, with other sociodemographic and lifestyle factors, 
such as socioeconomic deprivation. Importantly, studies 
that examine the impacts of multimorbidity on mortality 
in people with stroke are scant. A small number of stud-
ies have demonstrated an increased risk of mortality with 
higher numbers of morbidities [8–12]. These studies have 
been limited in that they have included low participant 
numbers [9–12], considered the effects of a limited number 
of comorbidities, involved a short length of follow-up, and 
were not adjusted for confounding factors [8–12]. Whether 
outcomes vary depending on the type of comorbidity, i.e. 
concordant and discordant, remains unclear.
Objectives
This paper aims to enhance our understanding of the 
risk factors for multimorbidity in those with stroke and, 
importantly, any effects on mortality. Here we examine, 
in those with stroke or transient ischaemic attack (TIA):
 • The relationship between sociodemographic and life-
style characteristics, and multimorbidity 
 • The relationship between multimorbidity and all-
cause mortality
 • Which comorbid health conditions, if any, have a 
stronger association with all-cause mortality.
Materials and methods
Study design and data collection
This study examined data from the UK Biobank cohort. 
UK Biobank participants are volunteers who have given 
full informed consent to provide information about their 
health for the purposes of research, and for prospective 
data linkage. The UK Biobank has full ethical approval 
from the NHS National Research Ethics Service (16/
NW/0274). 
Participants included in this study were 8,751 adults 
aged 40–72 years in the UK with self-reported stroke 
or TIA. All attended one of 22 assessment centres across 
England, Scotland, or Wales. Detailed sociodemo-
graphic, lifestyle, and medical information was collected 
from these individuals between 2006 and 2010 at an 
assessment centre by means of touch screen question-
naires and nurse-led interviews. 
Clinical variables and outcomes
Sociodemographic information included sex, age, and 
socioeconomic status based on the Townsend score (a 
measure of deprivation in the UK) [13]. Self-reported 
lifestyle characteristics included alcohol intake (never or 
on special occasions only, one to three times a month, 
or at least once a week) and smoking status (never, cur-
rent or previous). These baseline assessment centre data 
were linked to national mortality registries; and the 
median length of follow-up was 7 years from baseline 
data (interquartile range 75–93 months).
Data included information on self-reported mor-
bidities. For the purpose of examining the number of 
comorbidities reported, a count (1, 2, 3, 4 or ≥5) was 
taken from a list of 42 morbidities originally established 
for a previous large epidemiological study, through sys-
tematic review, the Quality and Outcomes Framework, 
NHS Scotland, and an expert panel [1], and subsequently 
amended for the UK Biobank [14] (see Supplementary 
File).
Statistical analysis
Frequencies, percentages, cross-tabulations, and graphi-
cal display were used for descriptive analysis. Relative 
risk ratios (RRRs; multinomial regression) were used 
to examine the associations between participant char-
acteristics and number of comorbidities. Hazards ratios 
(HRs; Cox proportional hazards regression) were used 
to examine associations between number of comorbidi-
ties and time to all-cause mortality. Participants with 
no comorbidities were used as the reference category. 
A Kaplan–Meier plot was used to compare cumulative 
mortality between participants with stroke or TIA with 
different numbers of comorbidities. Models containing 
all variables (sex, age, socioeconomic status, smoking, 
alcohol intake) with and without comorbidity count were 
compared by goodness of fit (R2) to ascertain if knowl-
edge of comorbidity improved prediction of mortality.
Individual Cox proportional hazards multivariable 
regression models were also used to study the adjusted 
effect size for the presence of each individual comorbidity 
(excluding those with a prevalence of less than 1% among 
participants with stroke or TIA) on all-cause mortality as 
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the outcome variable. Similarly, the adjusted effect size for 
the presence of any cardiometabolic comorbidity (diabe-
tes, coronary heart disease [CHD], atrial fibrillation [AF], 
chronic heart failure [CHF], chronic kidney disease [CKD], 
or hypertension) and any non-cardiometabolic comor-
bidity (all other conditions) were examined. RRRs and 
HRs were fully adjusted for age, sex, deprivation, smoking 
status, and alcohol intake. Individuals with missing values 
were excluded from the analyses. Statistical analyses were 
conducted using R software (version 3.2.2) using the 
packages ‘survival’ [15] and ‘nnet’ [16]. All analyses were 
independently checked by another member of the team. 
Results
Patient characteristics
Participants were 8,751 people who reported stroke or 
TIA. A total of 8,854 had reported these conditions in 
the UK Biobank; 103 of these were excluded from all 
analyses due to missing values. Mean age of included 
participants was 60.9 (standard deviation [SD] 6.7); 
57.5% were male; 95.6% were white British; mean 
Townsend score was 3.29 (SD 1.43); 7,497 (85.1%) had 
at least one comorbidity; mean number of comorbidi-
ties was 2.0 (SD 1.6). Of those with stroke or TIA, 734 
(8.4%) participants died over the period of follow-up. 
Participant details are shown in Table 1. 
Patient characteristics and number of comorbidities 
Fully adjusted RRRs for number of comorbidities in 
relation to patient characteristics are shown in Table 2. 
Higher numbers of comorbidities were found in those 
who were female, older, socio-economically deprived, 
smokers, and less frequent consumers of alcohol. These 
relationships remained positive after full adjustment for 
confounding factors. 
Number of comorbidities and mortality
Compared with those with no comorbidities, the risk 
of all-cause mortality was significantly higher for those 
with 2, 3, 4 or ≥5 comorbidities, and the risk increased 
as the number of morbidities increased. Fully adjusted 
HRs for mortality in relation to number of comorbidi-
ties are shown in Figure 1. A Kaplan–Meier plot showing 
probability of all-cause mortality among participants with 
different numbers of multimorbidity is shown in Figure 2. 
Prediction of mortality improved by 15.6% (R2 0.037 
as opposed to 0.032) when comorbidity count was added 
into the model that included sex, age, socioeconomic 
status, smoking, and alcohol intake. 
Type of comorbidity and mortality
Fully adjusted HRs for the presence of individual comor-
bidities are presented in Table 3. When compared with 
no comorbidities, presence of the following individual 
conditions alongside stroke or TIA significantly increased 
the risk of all-cause mortality: cancer, CHD, diabetes, or 
chronic obstructive pulmonary disease (COPD). 
Compared with no comorbidities, the presence of any 
cardiometabolic comorbidity significantly increased the 
risk of all-cause mortality (fully adjusted HR 1.42; 95% 
CI 1.19–1.69) as did the presence of any non-cardiomet-
abolic comorbidity (HR 1.38; 95% CI 1.17–1.61).
Discussion
Summary of results
In those with stroke or TIA, number of comorbidities 
was associated with female sex, older age, socioeco-
nomic deprivation, smoking, and less frequent alcohol 
consumption. 
Increasing multimorbidity was associated with an 
increasing risk of all-cause mortality, with mortality risk 
more than doubled for those with at least 5 morbidities 
Table 1 Sample characteristics (n=8,751).
Patient characteristic n (%)
Male 5,028 (57.5)
Age groups, years
 40–49 692 (7.9)
 50–59 2,243 (25.6)
 60–72 5,816 (66.5)
Ethnicity
 White 8,333 (95.6)
 Other 387 (4.4)
Townsend quintiles
 1 (most deprived) 2,528 (28.9)
 2 1,752 (20)
 3 1,612 (18.4)
 4 1,509 (17.2)
 5 (least deprived) 1,350 (15.4)
Smoking status
 Never 3,684 (42.1)
 Current or previous 5,067 (57.9)
Alcohol intake
 Never or special occasions only 2,552 (29.2)
 One to three times a month 946 (10.8)
 At least once a week 5,253 (60.0)
Number of comorbidities
 0 1,254 (14.3)
 1 2,416 (27.6)
 2 2,313 (26.4)
 3 1,407 (16.1)
 4 734 (8.4)
 ≥5 627 (7.2)
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which includes 17 morbidities and is weighted, i.e. a 
higher score is given for morbidities deemed to be more 
severe. To the best of our knowledge, ours is the first 
study to examine other sociodemographic and lifestyle 
factors in individuals with stroke or TIA and multimor-
bidity. The finding that multimorbidity is associated 
with age and socioeconomic deprivation correlates with 
the wider literature on multimorbidity [1,17,18].
Five studies were found that have examined mortal-
ity in relation to multimorbidity in stroke [8–12], but 
none were adjusted for such a broad range of potential 
confounders. All had a higher mean age (68–82 years) 
[8–12] and all but one [8] included smaller numbers 
of participants (175–2,402) and a shorter length of 
follow-up (the longest was 1 year) than presented in 
compared with those with none. The presence of cancer, 
CHD, diabetes, or COPD significantly increased the 
risk of mortality for those with stroke or TIA. Interest-
ingly, the presence of any cardiometabolic comorbidity 
significantly increased the risk of all-cause mortality, as 
did the presence of any non-cardiometabolic comorbid-
ity, with little difference in effect size between these two 
groups. 
How findings compare with other studies
Studies of risk factors for multimorbidity in stroke or TIA 
are limited. Only one could be found that examined age 
as a risk factor [7]. This found a significant association 
between age and Charlson Comorbidity Index (CCI), 
0 comorbidities
1 comorbidity
2 comorbidities
3 comorbidities
4 comorbidities
5 or more comorbidities
0.5 1 1.25 1.5 1.75 2 2.25 2.5 2.75 3 3.25 3.5 3.75 4
Hazard ratios with 95% confidence intervals
Figure 1 Fully adjusted hazards ratios for mortality in relation to the number of comorbidities. 
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Figure 2 Kaplan–Meier graph of death proportion versus comorbidities (n=8,751).
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this paper. All had baseline data collected in the acute 
setting, whereas this study examined a community 
cohort. All reported a positive relationship between 
comorbidity and mortality [8–12]. All used the CCI 
to measure comorbidity and one additionally used 
two other unweighted measures of a larger number of 
comorbidities [10]. Unweighted measures performed 
better than the CCI when predicting 6-month mortal-
ity. Two of the above studies also examined mortality 
risk in relation to the presence of individual comorbid-
ities [8,11]. The smaller of these two studies (N=332) 
[11] found a significant in-hospital mortality risk asso-
ciated with CHF, cancer, and CKD. The larger study 
(N=219,354) [8] found a significant 5-year mortality 
risk associated with CHF, AF, peripheral vascular dis-
ease, dementia, COPD, ulcer disease, liver disease, 
diabetes, moderate-to-severe renal disease, and cancer. 
In our study, a smaller number of conditions was found 
to have a significant effect on mortality. This could be 
explained by the inclusion of a larger number of poten-
tial confounders in the analyses. To our knowledge, this 
is the first study to examine the effects on mortality of 
cardiometabolic versus non-cardiometabolic comorbid-
ity in people with stroke. 
Studies of the wider population have similarly shown 
a strong relationship between number of morbidities and 
mortality. This holds true for studies that have examined 
older adults [19] and those that have included younger 
participants [20]; however, like those that have exam-
ined stroke populations, studies have included small 
sample sizes or examined low numbers of conditions, 
and adjustment for potentially confounding factors is 
often lacking [19]. 
Implications
This paper is novel because, for the first time, to our 
knowledge, it scrutinizes, in a large community cohort 
of people with stroke or TIA, the risk factors for multi-
morbidity and the relationship that multimorbidity has 
with mortality, whilst taking into account the potential 
confounding effects of sociodemographic and lifestyle 
factors. A strong relationship was seen between the 
number of comorbidities and mortality, with those who 
had the highest number of multimorbidities being at the 
highest risk. Addition of number of comorbidities to the 
model (comprising age, sex, socioeconomic deprivation, 
smoking, and alcohol intake) improved prediction of 
mortality by 15%. However, presence of only a hand-
ful of individual comorbidities significantly increased 
risk of mortality, and little difference was seen between 
the effects of cardiometabolic and non-cardiometabolic 
comorbidity on mortality. These results suggest that 
the number of comorbidities is a more helpful predictor 
of mortality than type of condition. This has poten-
tially important implications for the risk stratification 
of people with stroke, and merits further exploration. 
Examination of whether particular combinations of 
comorbidities are associated with worse health-related 
outcomes is an important next step. 
The associations seen here between multimorbid-
ity and all-cause mortality support the premise that 
Table 3 Effects on mortality (fully adjusted hazards ratios) for the presence of individual comorbidities* (n=8,751).
Comorbidity n (%) Hazard ratio Confidence intervals p value
Hypertension 4,936 (56.4) 1.15 0.99–1.34 0.07
Painful condition 1,903 (21.7) 0.96 0.81–1.15 0.68
Coronary heart disease 1,510 (17.3) 1.60 1.36–1.88 <0.05
Diabetes 1,190 (13.6) 1.72 1.45–2.04 <0.05
Asthma 1,155 (13.2) 1.17 0.95–1.43 0.14
Dyspepsia 1,026 (11.7) 0.93 0.75–1.17 0.58
Cancer 882 (10.0) 2.16 1.80–2.60 <0.05
Depression 757 (8.7) 1.25 0.98–1.60 0.07
Thyroid disorder 634 (7.2) 0.79 0.56–1.10 0.16
COPD 388 (4.4) 1.48 1.13–1.92 <0.05
Epilepsy 332 (3.8) 1.03 0.71–1.50 0.86
Rheumatoid arthritis and other connective tissue diseases 331 (3.8) 1.22 0.86–1.74 0.27
Migraine 293 (3.3) 0.79 0.47–1.32 0.37
Psoriasis/eczema 291 (3.3) 1.19 0.82–1.73 0.35
Prostate disease 260 (3.0) 1.01 0.70–1.46 0.96
Osteoporosis 260 (3.0) 1.12 0.74–1.70 0.57
Atrial fibrillation 257 (2.9) 0.80 0.50–1.28 0.36
Anxiety 179 (2.0) 0.81 0.46–1.43 0.46
Inflammatory bowel disease 173 (2.0) 1.01 0.48–2.12 0.98
Diverticular disease 162 (1.9) 0.62 0.32–1.20 0.16
Glaucoma 142 (1.6) 0.70 0.36–1.35 0.28
*Results in bold are significant. COPD, chronic obstructive pulmonary disease.
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relationships. As discussed above, multimorbidity has 
received much attention in the literature, yet no con-
sensus has been reached on the optimal method of 
measurement [29]. A simple count was deemed suitable 
due to the availability of data on a wide range of morbid-
ities; however, this count was unweighted, which could 
be viewed as a limitation. The use of a wide range of 
confounding factors is a strength of this study. The nega-
tive relationship between multimorbidity and frequency 
of alcohol consumption may be due to poor correlation 
between frequency of consumption and amount con-
sumed. A sensitivity analysis on a subset of individuals 
with data available on weekly unit consumption was 
conducted, but unfortunately interpretation was limited 
due to a small sample size and wide confidence intervals.
Conclusions
Survival in participants aged 40–72 years with self-reported 
stroke or TIA was strongly correlated with the number 
of comorbidities, suggesting that greater emphasis on 
patient-centred rather than disease-centred care is merited. 
Significantly worse outcomes were seen in those who had 
cancer, CHD, diabetes, or COPD alongside their stroke 
or TIA. There was little difference between the effects of 
cardiometabolic and non-cardiometabolic comorbidity on 
mortality; both were significant. The number of comor-
bidities may be a better predictor of mortality than type 
of comorbidity. Those with stroke or TIA who were older, 
socio-economically deprived, smokers, and less frequent 
alcohol consumers were at higher risk of multimorbidity. 
Clinical guidelines need to place greater emphasis on the 
issues of multimorbidity in stroke and TIA.
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prioritization should be given to the optimization of 
services provided for those with stroke affected by high 
levels of multimorbidity. Current clinical guidelines for 
stroke do not address management of multimorbidity 
[21–24] due to a lack of evidence on health-related out-
comes and interventions that improve these outcomes. 
Individuals with multimorbidity could benefit from tar-
geted interventions, such as increased clinician time [25]. 
Current risk stratification of individuals with multimor-
bidity is suboptimal; for example, the CCI is frequently 
used by clinicians and researchers, yet this does not 
include CHD, a condition that we found to be associ-
ated with a significantly increased risk of mortality, and 
previous work has shown unweighted measures to be 
superior to the CCI for predicting mortality in the acute 
setting [10]. Further work should compare the utility of 
different measures of multimorbidity in a community 
setting. Additionally, examination of any associations 
between multimorbidity and other rehabilitation out-
comes, such as functional change, merits examination 
[26]. Further research is needed to allow: (1) better risk 
stratification of individuals with multimorbidity with 
a history of stroke or TIA; and (2) development and 
testing of complex interventions aimed at improving 
health-related outcomes for these individuals.
Possible limitations
The use of self-reported health data could be a potential 
limitation; however, participants were supported by a 
nurse when reporting their health conditions [27]. The 
average age of this cohort was younger than the aver-
age stroke patient [2]. Younger individuals with stroke 
have, to date, been under-investigated. Participants 
were mostly white British, therefore ethnic minorities 
living in the UK were under-represented, and the par-
ticipant sample was relatively affluent. These limitations 
are almost certainly due to participation bias and are 
likely to provide a more conservative picture of multi-
morbidity and effects on mortality [2,28]. For example, 
in a previous study of primary care records that included 
a more socio-economically deprived sample represen-
tative of the Scottish population, 94% of people with 
stroke had multimorbidity [2]; and in this study, 85% 
had multimorbidity. An under-representation of socially 
deprived individuals in the UK Biobank and the rela-
tively younger age range are likely to contribute to the 
lower prevalence of multimorbidity in this study of peo-
ple with stroke. The UK Biobank is representative of the 
UK population in regard to gender. The large sample 
size was a strength of the study.
The examination of patient characteristics in rela-
tion to number of morbidities was cross-sectional and 
therefore it was not possible to determine temporal 
8  K.I. Gallacher et al.
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